Aberrant CD20 Expression in Angioimmunoblastic T-cell Lymphoma
Aberrant CD20 Expression in Angioimmunoblastic T-cell Lymphoma
复制标题
DOI：
10.2169/internalmedicine.50.4386
复制
发表时间：
2011-01-01
影响因子：
1.2
通讯作者：
Ishigatsubo, Yoshiaki
中科院分区：
文献类型：
--
作者：
Tachibana, Takayoshi;Tomita, Naoto;Ishigatsubo, Yoshiaki
我们报道了一名 60 岁男性，患有血管免疫母细胞 T 细胞淋巴瘤 (AITL)，且 CD20 表达异常。最初的活检标本显示具有典型CD3(+)CD20(-)免疫表型的AITL特征。随着疾病的进展，复发性病变的活检标本在流式细胞术和免疫组织化学分析中均显示出具有CD20(+)免疫表型的AITL异常结果。双重免疫染色证实淋巴瘤细胞同时呈CD3和CD20阳性。该疾病对联合化疗产生了耐药性，患者在初次诊断后 3 年后死亡。尸检显示为 AITL 和 EBV 阳性弥漫性大 B 细胞淋巴瘤的复合病。尽管尚不清楚 CD20 抗原表达的不稳定性是否与 AITL 的行为相关，但在这种情况下，应考虑使用利妥昔单抗作为替代治疗选择。
We report on a 60-year-old man, having angioimmunoblastic T-cell lymphoma (AITL) with aberrant expression of CD20. The initial biopsy specimen showed features of AITL with the typical CD3(+)CD20(-) immunophenotype. As the disease progressed, biopsy specimens of the recurrent lesions showed unusual results for AITL with the CD20(+) immunophenotype in both flow cytometry and immunohistochemistry analysis. Double immunostaining confirmed that the lymphoma cells were simultaneously positive for CD3 and CD20. The disease became resistant to combined chemotherapies and the patient died 3 years after the initial diagnosis. Autopsy revealed a composite of AITL and EBV-positive diffuse large B-cell lymphoma. Although it is unknown whether the instability of the CD20 antigen expression is correlated with the behaviour of AITL, the administration of rituximab should be considered as an alternative therapeutic option in such cases.